Integrated Health Science Facility Core

综合健康科学中心综合健康科学设施核心（IHSFC）的总体目标 环境健康科学（CIEHS）是将污染和生活方式因素的基础研究 影响人类健康和慢性疾病。多学科IHSFC提供基础设施，促进 为CIEHS、大学和社区提供翻译人类受试者EHS研究。最终目标是 改善公共卫生和临床实践。IHSFC支持以患者为导向的临床研究; 以人口为基础的研究;以及社区参与/领导的研究。IHSFC由两个相互作用的 下属单位：研究行政和规划分单位和研究执行分单位 亚单位（RIS）。IHSFC与其他CIEHS核心和研究兴趣小组（RIGs）互动，以（i） 提供最先进的仪器和技术; ㈡加强多学科合作; 及（iii）加强与社区组织的伙伴关系。IHSFC的首要目标是 管理IHSFC并计划翻译人类受试者EHS研究。这一目标由RAPS实现。 RAPS使IHSFC能够接触CIEHS成员、受训人员和社区。RAPS征求申请 人类受试者的研究;然后审查，优先考虑和财政补贴支持的应用程序。 RAPS在NIEHS转化研究框架的背景下定义了IHSFC研究。社区- 建议的研究想法被分配给适当的CIEHS成员进行开发和执行。 RAPS提供转化研究培训/教育;并跟踪和报告绩效指标， 评价的行政核心。RAPS提供科学，研究设计和社区参与 通过与各区域执行小组和其他CIEHS核心的联系进行协商。这些磋商确保所有IHSFC- 支持的研究：（i）严格设计和动力;（ii）与CIEHS的主题一致， 研究兴趣;（iii）考虑影响这项研究的社区组织的参与。的 IHSFC的第二个具体目标是实施IHSFC的研究。这一目标是由RIS实现的。RIS提供 人类受试者研究服务和获得最先进的生物分析仪器和技术 通过与综合毒理学和环境测量设施核心（ITEMFC）的联系。反过来， ITEMFC测量暴露和基于组学的疾病生物标志物。RIS利用UofL的成人临床试验 Kosair慈善儿科临床研究单位（KCPCRU），以及现有的 在一些实施方案中，研究人员可以使用队列/生物储存库来获得人类受试者数据和生物样品。接下来，RIS提供了与 用于生物标志物测量、数据分析和知识传播的其他CIEHS核心。基于 从事EHS研究和临床研究单位的医生-科学家的组合在别处找不到， IHSFC具有开展有影响力的转化EHS研究的独特能力，包括生物标志物 研究和干预性临床试验。

The overarching objective of the Integrated Health Sciences Facility Core (IHSFC) of the Center for Integrated Environmental Health Sciences (CIEHS) is to translate basic research on pollution and lifestyle factors influencing human health and chronic diseases. The multi-disciplinary IHSFC provides infrastructure facilitating translational human subjects EHS research for the CIEHS, university, and community. The ultimate goal is to improve public health and clinical practice. The IHSFC supports patient-oriented clinical research; group and population-based research; and community engaged/led research. The IHSFC is comprised of two interacting subunits: the Research Administration and Planning Subunit (RAPS) and the Research Implementation Subunit (RIS). The IHSFC interacts with other CIEHS cores and the Research Interest Groups (RIGs) to (i) provide access to state-of-the-art instrumentation and technologies; (ii) increase multidisciplinary collaboration; and (iii) enhance partnerships with community-based organizations. The IHSFC’s first specific aim is to administer the IHSFC and plan translational human subjects EHS research. This aim is performed by RAPS. RAPS provides IHSFC access to CIEHS members, trainees, and the community. RAPS solicits applications for human subjects research; and then reviews, prioritizes and financially subsidizes supported applications. RAPS defines IHSFC research in the context of the NIEHS Translational Research Framework. Community- proposed research ideas are assigned to an appropriate CIEHS member for development and execution. RAPS provides translational research training/education; and tracks and reports performance metrics to the Administrative Core for evaluation. RAPS provides scientific, study design, and community engagement consultation through linkages to the RIGs and other CIEHS cores. These consultations ensure that all IHSFC- supported studies: (i) are rigorously designed and powered; (ii) are consistent with CIEHS’s theme and research interests; and (iii) consider the involvement of community organizations impacting this research. The IHSFC’s second specific aim is to implement IHSFC research. This aim is performed by the RIS. RIS provides human subjects research services and access to state-of-the-art bio-analytic instrumentation and technologies through linkage to the Integrated Toxicomics & Environmental Measurement Facility Core (ITEMFC). In turn, ITEMFC measures exposure and ‘omics-based disease biomarkers. RIS leverages UofL’s adult Clinical Trials Unit (CTU), the Kosair Charities Pediatric Clinical Research Units (KCPCRU), and existing cohorts/biorepositories to obtain human subjects data and biological samples. Next, RIS provides linkage to other CIEHS cores for biomarker measurement, data analysis, and knowledge dissemination. Based on the combination of physician-scientists engaged in EHS research and clinical research units found nowhere else, the IHSFC has the unique capacity to conduct impactful translational EHS research, including biomarker studies and interventional clinical trials.